Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast cancer who had over expression of HER2. We repo...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
De Gruyter
2020-07-01
|
| Ráidu: | Open Medicine |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1515/med-2020-0201 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|